These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19268180)

  • 1. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of Canadian psychiatry].
    Stip E
    Encephale; 2009 Jan; Suppl 3():S115-8. PubMed ID: 19268180
    [No Abstract]   [Full Text] [Related]  

  • 2. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
    Buis C; Gourion D; Vaiva G
    Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
    [No Abstract]   [Full Text] [Related]  

  • 3. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). What are the limiting factors in resort to an APAP and how to overcome them].
    Canceil O; Limosin F; Passerieux C
    Encephale; 2009 Jan; Suppl 3():S101-7. PubMed ID: 19268178
    [No Abstract]   [Full Text] [Related]  

  • 4. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
    Chéreau I; Gorwood P; Mouchabac S
    Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
    [No Abstract]   [Full Text] [Related]  

  • 5. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
    Dassa D; Lacambre M; Vacheron MN
    Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
    [No Abstract]   [Full Text] [Related]  

  • 6. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of the pharmacologist. From neuroleptics to non-neuroleptic antipsychotics].
    Costentin J
    Encephale; 2009 Jan; Suppl 3():S119-22. PubMed ID: 19268181
    [No Abstract]   [Full Text] [Related]  

  • 7. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Foreword].
    Guelfi JD; Costentin J; Terra JL
    Encephale; 2009 Jan; Suppl 3():S85-6. PubMed ID: 19268183
    [No Abstract]   [Full Text] [Related]  

  • 8. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to evaluate the quality of observations].
    Benoit M; Pon J; Zimmermann MA
    Encephale; 2009 Jan; Suppl 3():S87-90. PubMed ID: 19268184
    [No Abstract]   [Full Text] [Related]  

  • 9. [Expert opinion on APAP (Prolonged action atypical antipsychotic agents). Conclusion].
    Guelfi JD
    Encephale; 2009 Jan; Suppl 3():S123-4. PubMed ID: 19268182
    [No Abstract]   [Full Text] [Related]  

  • 10. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Noncompliance--a typical problem in psychiatric patients. Individual, social and illness-specific factors].
    Hartung HD
    Fortschr Med; 1998 Jan; 116(3):28-30. PubMed ID: 9522542
    [No Abstract]   [Full Text] [Related]  

  • 12. Psychopharmacological treatment of schizophrenia.
    Lehmann HE
    Schizophr Bull; 1975; (13):27-45. PubMed ID: 1851
    [No Abstract]   [Full Text] [Related]  

  • 13. Legal fallacies of antipsychotic drugs.
    Erickson SK; Ciccone JR; Schwarzkopf SB; Lamberti JS; Vitacco MJ
    J Am Acad Psychiatry Law; 2007; 35(2):235-46. PubMed ID: 17592170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of partial compliance.
    Marder SR
    J Clin Psychiatry; 2003; 64 Suppl 16():3-9. PubMed ID: 14680412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The depot paradox.
    Glazer WM
    Behav Healthc; 2007 May; 27(5):44-6. PubMed ID: 17958249
    [No Abstract]   [Full Text] [Related]  

  • 17. Risks of intermittent antipsychotic treatment in schizophrenia.
    Suzuki T; Nomura K; Watanabe K
    J Clin Psychiatry; 2011 Jan; 72(1):114; author reply 114-5. PubMed ID: 21272519
    [No Abstract]   [Full Text] [Related]  

  • 18. [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].
    Azorin JM
    Encephale; 2013 Sep; 39 Suppl 2():S121-3. PubMed ID: 24084422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm maintenance therapy with depot haloperidol in schizophrenia.
    Zbytovský J
    Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcome comparison of patients receiving oral or depot neuroleptic medication.
    Varner RV; Hays JR; Wagner AL; Averill P
    Psychol Rep; 2001 Aug; 89(1):169-74. PubMed ID: 11729538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.